British Society for Haematology guidelines for the management of adult myelodysplastic syndromes

University Hospitals Dorset NHS Foundation Trust, The Royal Bournemouth Hospital, Bournemouth, University Hospital of Wales, Cardiff, Aberdeen Royal Infirmary, Aberdeen, Tallaght University Hospital, Dublin, Trinity College Medical School, Tallaght, University College London Cancer Institute, Kings College Hospital NHS Foundation Trust, London, University Hospitals Birmingham NHS Foundation Trust, Birmingham, Oxford University, Oxford University Hospitals NHS Trust & NHS Blood and Transplant, Oxford, Hull and East Yorkshire Hospitals NHS Trust, Hull, St.James’s Institute of Oncology, Leeds Teaching Hospitals, Leeds, Newcastle Hospitals NHS Foundation Trust, Newcastle Upon Tyne, Worcestershire Acute Hospitals NHS Trust and Birmingham NHS Foundation Trust, Worcester, Great Western Hospitals NHS Foundation Trust, Swindon, and The Christie NHS Foundation Trust, Manchester, UK

[1]  A. Gennery,et al.  Guidelines on the use of irradiated blood components , 2020, British journal of haematology.

[2]  E. Wood,et al.  Red cell transfusion in outpatients with myelodysplastic syndromes: a feasibility and exploratory randomised trial , 2020, British journal of haematology.

[3]  M. Cazzola,et al.  Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes. , 2020, The New England journal of medicine.

[4]  Benjamin L. Ebert,et al.  Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes , 2019, Nature Medicine.

[5]  U. Germing,et al.  Comparison between Upfront Transplantation and different Pretransplant Cytoreductive Treatment Approaches in Patients with High-Risk Myelodysplastic Syndrome and Secondary Acute Myelogenous Leukemia. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[6]  A. Savic,et al.  Impact of treatment with iron chelation therapy in patients with lower-risk myelodysplastic syndromes participating in the European MDS registry , 2019, Haematologica.

[7]  M. Cazzola,et al.  Clinical, histopathological and molecular characterization of hypoplastic myelodysplastic syndrome , 2019, Leukemia.

[8]  P. Greenberg,et al.  Clinical effectiveness and safety of erythropoietin‐stimulating agents for the treatment of low‐ and intermediate‐1−risk myelodysplastic syndrome: a systematic literature review , 2018, British journal of haematology.

[9]  A. Verma,et al.  Azacitidine with or without eltrombopag for first-line treatment of intermediate- or high-risk MDS with thrombocytopenia. , 2018, Blood.

[10]  N. Kröger,et al.  Relative Impact of HLA Matching and Non-HLA Donor Characteristics on Outcomes of Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome. , 2018, Biology of Blood and Marrow Transplantation.

[11]  R. Schlenk,et al.  Prospective Multicenter Phase 3 Study Comparing 5-Azacytidine (5-Aza) Induction Followed By Allogeneic Stem Cell Transplantation Versus Continuous 5-Aza According to Donor Availability in Elderly MDS Patients (55-70 years) (VidazaAllo Study) , 2018, Blood.

[12]  C. Flowers,et al.  Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  S. Fallahpour,et al.  Azacitidine in the ‘real‐world’: an evaluation of 1101 higher‐risk myelodysplastic syndrome/low blast count acute myeloid leukaemia patients in Ontario, Canada , 2018, British journal of haematology.

[14]  K. Götze,et al.  Enhanced labile plasma iron and outcome in acute myeloid leukaemia and myelodysplastic syndrome after allogeneic haemopoietic cell transplantation (ALLIVE): a prospective, multicentre, observational trial. , 2018, The Lancet. Haematology.

[15]  K. Götze,et al.  A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-α in anemic patients with low-risk MDS , 2018, Leukemia.

[16]  M. Konopleva,et al.  Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms , 2018, Oncotarget.

[17]  A. Nagler,et al.  Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial. , 2018, The Lancet. Haematology.

[18]  D. Swinkels,et al.  Labile plasma iron levels predict survival in patients with lower-risk myelodysplastic syndromes , 2017, Haematologica.

[19]  E. Wood,et al.  Red cell alloimmunization is associated with development of autoantibodies and increased red cell transfusion requirements in myelodysplastic syndrome , 2017, Haematologica.

[20]  B. Leber,et al.  ITACA: A new validated international erythropoietic stimulating agent‐response score that further refines the predictive power of previous scoring systems , 2017, American journal of hematology.

[21]  K. Kreuzer,et al.  Thrombopoietin mimetics for patients with myelodysplastic syndromes. , 2017, The Cochrane database of systematic reviews.

[22]  M. Delforge,et al.  A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes , 2017, Leukemia.

[23]  R. Larson,et al.  Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long‐term safety and efficacy , 2017, British journal of haematology.

[24]  E. Wood,et al.  Red cell transfusion thresholds in myelodysplastic syndromes: a clinician survey to inform future clinical trials , 2017, Internal medicine journal.

[25]  N. Kröger,et al.  Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients With Myelodysplastic Syndrome: A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial). , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  S. Miyano,et al.  Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation. , 2017, Blood.

[27]  A. Ganser,et al.  Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. , 2017, Blood.

[28]  A. Stamatoullas,et al.  Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  C Pascutto,et al.  Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System , 2017, Leukemia.

[30]  A. Stamatoullas,et al.  Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial. , 2017, The Lancet. Haematology.

[31]  E. Leifer,et al.  Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  D. Neuberg,et al.  Prognostic Mutations in Myelodysplastic Syndrome after Stem‐Cell Transplantation , 2017, The New England journal of medicine.

[33]  H. Garelius,et al.  Erythropoiesis‐stimulating agents significantly delay the onset of a regular transfusion need in nontransfused patients with lower‐risk myelodysplastic syndrome , 2016, Journal of internal medicine.

[34]  D. Neuberg,et al.  Progression in patients with low- and intermediate-1-risk del(5q) myelodysplastic syndromes is predicted by a limited subset of mutations , 2016, Haematologica.

[35]  H. Einsele,et al.  Allogeneic Stem Cell Transplantation for Patients Age ≥ 70 Years with Myelodysplastic Syndrome: A Retrospective Study of the MDS Subcommittee of the Chronic Malignancies Working Party of the EBMT. , 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[36]  R. Bellazzi,et al.  Clinical Effects of Driver Somatic Mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With Allogeneic Hematopoietic Stem-Cell Transplantation. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  Alan M. Miller,et al.  Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  N. Kröger,et al.  Prognostic pre-transplant factors in myelodysplastic syndromes primarily treated by high dose allogeneic hematopoietic stem cell transplantation: a retrospective study of the MDS subcommittee of the CMWP of the EBMT , 2016, Annals of Hematology.

[39]  M. Cazzola,et al.  Time-dependent changes in mortality and transformation risk in MDS. , 2016, Blood.

[40]  E. Roman,et al.  Myeloid malignancies in the real-world: Occurrence, progression and survival in the UK’s population-based Haematological Malignancy Research Network 2004–15 , 2016, Cancer epidemiology.

[41]  O. Visser,et al.  Red-blood-cell alloimmunisation in relation to antigens' exposure and their immunogenicity: a cohort study. , 2016, The Lancet. Haematology.

[42]  Mario Cazzola,et al.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. , 2016, Blood.

[43]  S. Nahas,et al.  Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes , 2016, Leukemia.

[44]  P. Vyas,et al.  Alternative agents versus prophylactic platelet transfusion for preventing bleeding in patients with thrombocytopenia due to chronic bone marrow failure: a network meta-analysis and systematic review. , 2016, The Cochrane database of systematic reviews.

[45]  Inderjeet Dokal,et al.  Guidelines for the diagnosis and management of adult aplastic anaemia , 2016, British journal of haematology.

[46]  R. Fulton,et al.  TP 53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes , 2016 .

[47]  M. Tormo,et al.  Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registry , 2015, Leukemia.

[48]  H. Kantarjian,et al.  Outcome of patients with low‐risk and intermediate‐1‐risk myelodysplastic syndrome after hypomethylating agent failure: A report on behalf of the MDS Clinical Research Consortium , 2015, Cancer.

[49]  Benjamin Djulbegovic,et al.  Platelet Transfusion: A Clinical Practice Guideline From the AABB , 2015, Annals of Internal Medicine.

[50]  T. Haferlach,et al.  Response to azacitidine is independent of p53 expression in higher-risk myelodysplastic syndromes and secondary acute myeloid leukemia , 2014, Haematologica.

[51]  D. Neuberg,et al.  Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  C. Preudhomme,et al.  Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine. , 2014, Leukemia research.

[53]  M. Tormo,et al.  Multivariate time‐dependent comparison of the impact of lenalidomide in lower‐risk myelodysplastic syndromes with chromosome 5q deletion , 2014, British Journal of Haematology.

[54]  M. Vignetti,et al.  Deferasirox for transfusion‐dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial) , 2014, European journal of haematology.

[55]  W. Wiktor-Jedrzejczak,et al.  Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1–risk myelodysplastic syndrome and thrombocytopenia , 2014, Cancer.

[56]  P. Vyas,et al.  Guidelines for the diagnosis and management of adult myelodysplastic syndromes , 2014, British journal of haematology.

[57]  B. Skikne,et al.  Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS , 2013, Leukemia.

[58]  M. Cazzola,et al.  Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  Stefano Guidi,et al.  Optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome , 2013, American journal of hematology.

[60]  G. Mann,et al.  Ferritin concentrations correlate to outcome of hematopoietic stem cell transplantation but do not serve as biomarker of graft-versus-host disease , 2013, Annals of Hematology.

[61]  G. Mufti,et al.  TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis , 2013, British journal of haematology.

[62]  P. Greenberg,et al.  A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving decitabine , 2013, Leukemia & lymphoma.

[63]  C. Milkins,et al.  Guidelines for pre‐transfusion compatibility procedures in blood transfusion laboratories , 2013, Transfusion medicine.

[64]  A. Glasmacher,et al.  Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis , 2012, Leukemia.

[65]  R. Larson,et al.  A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide , 2012, Journal of Hematology & Oncology.

[66]  A. Duhamel,et al.  Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: a study by the Société Française de Greffe de Moelle et de Thérapie-Cellulaire and the Groupe-Francophone des Myélodysplasies. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[67]  Luca Malcovati,et al.  Revised international prognostic scoring system for myelodysplastic syndromes. , 2012, Blood.

[68]  S. Berendse,et al.  Prevention and management of neutropenic sepsis in patients with cancer: summary of NICE guidance , 2012, BMJ : British Medical Journal.

[69]  P. Fenaux,et al.  Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes , 2012, Haematologica.

[70]  U. Germing,et al.  Improved survival in MDS patients receiving iron chelation therapy - a matched pair analysis of 188 patients from the Düsseldorf MDS registry. , 2012, Leukemia research.

[71]  D. Steensma,et al.  Deferasirox reduces serum ferritin and labile plasma iron in RBC transfusion-dependent patients with myelodysplastic syndrome. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[72]  S. Chevret,et al.  Treatment with lenalidomide does not appear to increase the risk of progression in lower risk myelodysplastic syndromes with 5q deletion. A comparative analysis by the Groupe Francophone des Myelodysplasies , 2012, Haematologica.

[73]  R. Schlenk,et al.  Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): A multicenter study , 2012, Leukemia.

[74]  S. Fröhling,et al.  TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. , 2012, Blood.

[75]  M. Cazzola,et al.  A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. , 2011, Blood.

[76]  M. Cazzola,et al.  Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS) , 2011, Haematologica.

[77]  J. Astermark,et al.  Quality of life, physical function and MRI T2* in elderly low‐risk MDS patients treated to a haemoglobin level of ≥120 g/L with darbepoetin alfa ± filgrastim or erythrocyte transfusions , 2011, European journal of haematology.

[78]  J. Maciejewski,et al.  Perceptions of disease state, treatment outcomes, and prognosis among patients with myelodysplastic syndromes: results from an internet-based survey. , 2011, The oncologist.

[79]  Eva Hellström-Lindberg,et al.  TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[80]  N. Kröger,et al.  Allogeneic stem cell transplantation for myelodysplastic syndromes with bone marrow fibrosis , 2011, Haematologica.

[81]  A. Stamatoullas,et al.  Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. , 2011, Blood.

[82]  G. Mufti,et al.  Effects of azacitidine compared with conventional care regimens in elderly (≥ 75 years) patients with higher-risk myelodysplastic syndromes. , 2010, Critical reviews in oncology/hematology.

[83]  A. Stamatoullas,et al.  Early introduction of ESA in low risk MDS patients may delay the need for RBC transfusion: a retrospective analysis on 112 patients. , 2010, Leukemia research.

[84]  W. Hofmann,et al.  Practical use of azacitidine in higher-risk myelodysplastic syndromes: an expert panel opinion. , 2010, Leukemia research.

[85]  A. Ganser,et al.  Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study. , 2010, Leukemia research.

[86]  M. Laouri,et al.  Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[87]  G. Mufti,et al.  Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[88]  R. Larson,et al.  Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[89]  Comparative analysis of remission induction therapy for high-risk MDS and AML progressed from MDS in the MDS200 study of Japan Adult Leukemia Study Group , 2010, International journal of hematology.

[90]  J. Issa,et al.  Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high‐risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities , 2009, Cancer.

[91]  H. Kantarjian,et al.  Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[92]  L. Malcovati,et al.  Clinical relevance of extra-hematologic comorbidity in the management of patients with myelodysplastic syndrome , 2009, Haematologica.

[93]  J. Hainsworth,et al.  Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[94]  Valeria Santini,et al.  Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. , 2009, The Lancet. Oncology.

[95]  E. Estey,et al.  Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients. , 2009, Blood.

[96]  J. Gabrilove,et al.  Phase 2, single-arm trial to evaluate the effectiveness of darbepoetin alfa for correcting anaemia in patients with myelodysplastic syndromes , 2008, British journal of haematology.

[97]  M. Cazzola,et al.  Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[98]  H. Dombret,et al.  Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era; the GFM experience with EPO and thalidomide. , 2008, Leukemia research.

[99]  H. Dombret,et al.  Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. , 2008, Blood.

[100]  H. Deeg,et al.  Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[101]  U. Germing,et al.  Intensive chemotherapy is not recommended for patients aged >60 years who have myelodysplastic syndromes or acute myeloid leukemia with high‐risk karyotypes , 2007, Cancer.

[102]  J. Perfect,et al.  Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. , 2007, The New England journal of medicine.

[103]  U. Germing,et al.  Myelodysplastic syndromes in patients younger than age 50. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[104]  B. Cheson,et al.  Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. , 2006, Blood.

[105]  L. Mannone,et al.  High‐dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study , 2006, British journal of haematology.

[106]  John M Bennett,et al.  Decitabine improves patient outcomes in myelodysplastic syndromes , 2006, Cancer.

[107]  E. Estey,et al.  Long‐term follow‐up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome , 2006, Cancer.

[108]  M. Tormo,et al.  Darbepoetin alpha for the treatment of anemia in patients with myelodysplastic syndromes. , 2006, Cancer.

[109]  E. Estey,et al.  Results of Intensive Chemotherapy in 998 Patients Aged 65 Years or Older with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome - Predictive Prognostic Models for Outcome. , 2005 .

[110]  Luca Malcovati,et al.  Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[111]  T. S. St. Pierre,et al.  Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. , 2005, Blood.

[112]  John P Klein,et al.  A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. , 2004, Blood.

[113]  C. Schoch,et al.  Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31 , 2004, Leukemia.

[114]  A. la Sala,et al.  Efficacy of a single, weekly dose of recombinant erythropoietin in myelodysplastic syndromes , 2003, British journal of haematology.

[115]  Guidelines for the use of platelet transfusions , 2003, British journal of haematology.

[116]  H. Eiskjaer,et al.  Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with deferrioxamine: indication of close relation between myocardial iron content and chelatable iron pool. , 2003, Blood.

[117]  I. Dybedal,et al.  A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony‐stimulating factor: significant effects on quality of life , 2003, British journal of haematology.

[118]  G. Mufti,et al.  Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes , 2003, British journal of haematology.

[119]  D N Firmin,et al.  Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. , 2001, European heart journal.

[120]  M. Sagmeister,et al.  A restrictive platelet transfusion policy allowing long-term support of outpatients with severe aplastic anemia. , 1999, Blood.

[121]  E. Wattel,et al.  Long‐term follow‐up of de novo myelodysplastic syndromes treated with intensive chemotherapy: incidence of long‐term survivors and outcome of partial responders , 1997, British journal of haematology.

[122]  K. Kojima,et al.  Low-dose melphalan for treatment of high-risk myelodysplastic syndromes. , 1996, Leukemia.

[123]  W. Crosby,et al.  Regulation of the Intestinal Absorption of Iron by the Rate of Erythropoiesis , 1965, British journal of haematology.